Volume | 12,487 |
|
|||||
News | - | ||||||
Day High | 3.00 | Low High |
|||||
Day Low | 2.8301 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
GT Biopharma Inc | GTBP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.97 | 2.8301 | 3.00 | 2.89 | 3.00 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
146 | 12,487 | $ 2.95 | $ 36,806 | - | 2.61 - 14.37 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:45:35 | 10 | $ 2.83 | USD |
GT Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
4.1M | 1.38M | - | 0 | -7.6M | -5.50 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
GT Biopharma News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GTBP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.26 | 3.3299 | 2.61 | 2.98 | 77,170 | -0.37 | -11.35% |
1 Month | 3.32 | 10.6599 | 2.61 | 7.22 | 4,517,341 | -0.43 | -12.95% |
3 Months | 4.62 | 10.6599 | 2.61 | 7.21 | 1,487,137 | -1.73 | -37.45% |
6 Months | 6.75 | 10.6599 | 2.61 | 7.18 | 739,084 | -3.86 | -57.19% |
1 Year | 10.20 | 14.37 | 2.61 | 7.65 | 513,873 | -7.31 | -71.67% |
3 Years | 541.50 | 591.993 | 2.61 | 68.02 | 306,188 | -538.61 | -99.47% |
5 Years | 165.00 | 591.993 | 2.61 | 109.21 | 336,889 | -162.11 | -98.25% |
GT Biopharma Description
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. |